Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

th several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... available in French . ... year old teens, including brain structure and function, personality, life ... will go on to develop binge drinking within the next ... other variables such as life events and a family history ... Whether or not the child had had a single ...
(Date:7/9/2014)... 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at the ... July 17 in Copenhagen, Denmark. Data from the ... transition from cognitive normality to mild cognitive impairment and ... Aging Study , established in 1980 to examine healthy ...
(Date:7/9/2014)... p>YouTube is for more than watching World Cup highlights, ... of skateboarders landing in unfortunate positions on railings. A ... Dermatology Online Journal shows that YouTube also ... with the public on topics of skin cancer and ... media is the future of how we communicate around ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... "The time is right and the,wording is excellent," ... bill recognizes the God-given Right to Life of every ... end the slaughter of,innocent children.", S.3111, introduced by ... scheduled for debate in the Senate Committee on the ...
... employers also explores ROI, behaviors earning ... evaluation measures, WASHINGTON and LYNDHURST, N.J., June 26 ... and,wellness programs rose from 62 percent to 71 percent ... Also included is new data about what,programs employers reward, ...
... 26 Impliant, Inc., a developer of,novel ... announced,that it has resumed European clinical activities ... device designed to treat spinal stenosis with,or ... was,performed by the Lead Clinician of the ...
... Toronto, CANADA Adults with type 2 diabetes who ... afterward, but this can be offset by taking antioxidant ... Baycrest. , There is already growing evidence linking diabetes ... 2 diabetes are especially vulnerable to acute meal-induced memory ...
... to confer some protection against bladder cancer in mice, scientists ... had approximately 15 times as much cancer in their bladders ... findings by investigators at the University of Rochester Medical Center. ... journal Urology . , The researchers led by Jay ...
... Quarters of Fiscal 2008 ... 31, 2008 Points to Positive Fiscal 2009 Outlook for ... ... KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company ...
Cached Medicine News:Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 2Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 3Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 4Health News:Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 3Health News:Pregnancy may help protect against bladder cancer 2Health News:Pregnancy may help protect against bladder cancer 3Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 2Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 3Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 4
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Inquire...
Medicine Products: